Business Context and Reporting Period
Oncolytics Biotech Inc., a foreign private issuer based in Calgary, Alberta, Canada, filed this Form 6-K on August 6, 2009. The filing serves as an amended reconciliation of Canadian GAAP to US GAAP for the three-month and six-month periods ended June 30, 2009, and June 30, 2008. The primary purpose is to correct the basic and diluted loss per common share for the three-month period ended June 30, 2008, previously reported on July 31, 2009.
Key Financial Metrics
The filing provides reconciled US GAAP figures for net loss and loss per share. Cash flow amounts are identical under both Canadian and US GAAP.
| Metric | 3 Months Ended June 30, 2009 | 3 Months Ended June 30, 2008 | 6 Months Ended June 30, 2009 | 6 Months Ended June 30, 2008 |
|---|---|---|---|---|
| Net Loss (US GAAP) | $4,244,382 | $5,164,155 | $8,111,653 | $8,468,153 |
| Loss Per Share (Basic & Diluted) | $(0.09) | $(0.13) | $(0.18) | $(0.21) |
Balance Sheet Items (US GAAP as of June 30, 2009):
- Intellectual Property: $0 (reversed from Canadian GAAP due to "Push-Down" accounting adjustments regarding in-process R&D).
- Contributed Surplus: $10,869,982.
- Deficit: $108,349,154.
The filing does not provide specific values for revenue, operating cash flow, debt, or liquidity ratios.
Material Changes and Adjustments
The reconciliation highlights significant differences between Canadian and US GAAP treatments:
- Intellectual Property: Under US GAAP, $2,500,000 of intellectual property recorded from a 1999 acquisition is not capitalized. Consequently, amortization of $90,375 (three months) and $180,750 (six months) is reversed, reducing the net loss compared to Canadian GAAP.
- Stock-Based Compensation: US GAAP requires stock-based compensation to be presented within specific expense categories. This reclassification reduces stock-based compensation expense by $8,544 (three months) and $20,181 (six months) while increasing research and development expenses by the same amounts. There is no impact on the total net loss.
Outlook, Risks, and Contingencies
Contingent Obligations: The Company has outstanding obligations under an Assumption Agreement from 1999 regarding the REOLYSIN® product:
- Milestone Payment: A $1.0 million payment is due within 90 days of the first receipt of regulatory marketing approval for REOLYSIN®. This will be recorded as a research and development expense and is not tax-deductible.
- Royalties: If the Company receives royalty payments from partnerships, it must pay 11.75% to founding shareholders. If the Company markets the product commercially, it must pay a royalty of 2.35% of Net Sales to founding shareholders.
Subsequent Events: Management evaluated subsequent events through July 28, 2009, the date the financial statements were issued. No events after this date were evaluated.
Investor Verification Checklist
- Verify the corrected loss per share figures for the three-month period ended June 30, 2008, as this filing specifically amends that data.
- Confirm the status of regulatory approval for REOLYSIN® to assess the timing of the potential $1.0 million milestone payment.
- Review the company's cash position and burn rate, as the filing indicates a cumulative deficit of over $108 million but does not explicitly state current cash balances.
- Monitor future filings for updates on the 11.75% or 2.35% royalty obligations to founding shareholders.